Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies - PubMed (original) (raw)
Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
G Schlimok et al. Proc Natl Acad Sci U S A. 1987 Dec.
Abstract
The detection of early micrometastasis or disseminated single tumor cells poses a problem for conventional diagnosis procedures. Using a panel of monoclonal antibodies against cytokeratin and the 17-1A epithelial antigen we identified immunocytochemically tumor cells in bone marrow of patients with breast cancer (n = 155) and colorectal cancer (n = 57) at the time of surgery of the primary tumor. Monoclonal antibody CK2, recognizing the human cytokeratin component 18 in simple epithelia, appeared to be the most suitable reagent because of its negative reaction with bone marrow samples of the noncarcinoma patients (n = 75). Its specificity was further demonstrated in a double-marker staining procedure using an anti-leukocyte common antigen monoclonal antibody (T200) as counterstain. A comparative analysis showed that immunocytology was clearly superior to conventional cytology (n = 212) and histology (n = 39). In 9.5-20.5% of patients without distant metastasis, tumor cells could be detected in bone marrow. We found a significant correlation between tumor cells in bone marrow and conventional risk factors, such as distant metastasis or lymph node involvement. In a first approach toward immunotherapy we demonstrated in 3 patients that infused monoclonal antibody 17-1A can label single tumor cells in bone marrow in vivo. We then used this approach to follow up 7 patients undergoing 17-1A therapy in an adjuvant clinical trial.
Similar articles
- Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.
Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmüller G. Pantel K, et al. J Hematother. 1994 Fall;3(3):165-73. doi: 10.1089/scd.1.1994.3.165. J Hematother. 1994. PMID: 7530132 Clinical Trial. - [Monoclonal antibodies--new probes for diagnosis and therapy. Their use as an example of the micrometastasizing of solid tumors].
Schlimok G, Funke I, Bock B, Schweiberer B, Riethmüller G. Schlimok G, et al. Arzneimittelforschung. 1988 Mar;38(3A):435-7. Arzneimittelforschung. 1988. PMID: 3293575 Review. German. - Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmüller G, Willgeroth F, Sommer HL. Braun S, et al. Clin Cancer Res. 1999 Dec;5(12):3999-4004. Clin Cancer Res. 1999. PMID: 10632331 Clinical Trial. - Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.
Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmüller G. Pantel K, et al. J Natl Cancer Inst. 1993 Sep 1;85(17):1419-24. doi: 10.1093/jnci/85.17.1419. J Natl Cancer Inst. 1993. PMID: 7688814 - Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow.
Schlimok G, Riethmüller G. Schlimok G, et al. Semin Cancer Biol. 1990 Jun;1(3):207-15. Semin Cancer Biol. 1990. PMID: 2103496 Review.
Cited by
- Targeting cancer cell dormancy.
Agudo J, Aguirre-Ghiso JA, Bhatia M, Chodosh LA, Correia AL, Klein CA. Agudo J, et al. Nat Rev Cancer. 2024 Feb;24(2):97-104. doi: 10.1038/s41568-023-00642-x. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062251 Free PMC article. - Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.
Heidrich I, Deitert B, Werner S, Pantel K. Heidrich I, et al. Cancer Metastasis Rev. 2023 Mar;42(1):161-182. doi: 10.1007/s10555-022-10075-x. Epub 2023 Jan 6. Cancer Metastasis Rev. 2023. PMID: 36607507 Free PMC article. Review. - Genome-wide methylation analyses identifies Non-coding RNA genes dysregulated in breast tumours that metastasise to the brain.
Pangeni RP, Olivaries I, Huen D, Buzatto VC, Dawson TP, Ashton KM, Davis C, Brodbelt AR, Jenkinson MD, Bièche I, Yang L, Latif F, Darling JL, Warr TJ, Morris MR. Pangeni RP, et al. Sci Rep. 2022 Jan 20;12(1):1102. doi: 10.1038/s41598-022-05050-z. Sci Rep. 2022. PMID: 35058523 Free PMC article. - Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors.
Jiang B, Mu Q, Qiu F, Li X, Xu W, Yu J, Fu W, Cao Y, Wang J. Jiang B, et al. Nat Commun. 2021 Nov 18;12(1):6692. doi: 10.1038/s41467-021-27017-w. Nat Commun. 2021. PMID: 34795255 Free PMC article. - Prostate cancer dormancy and recurrence.
Cackowski FC, Heath EI. Cackowski FC, et al. Cancer Lett. 2022 Jan 1;524:103-108. doi: 10.1016/j.canlet.2021.09.037. Epub 2021 Oct 5. Cancer Lett. 2022. PMID: 34624433 Free PMC article. Review.
References
- Ann Intern Med. 1975 Mar;82(3):365-6 - PubMed
- Int J Cancer. 1986 Jul 15;38(1):47-53 - PubMed
- J Exp Med. 1980 Oct 1;152(4):842-52 - PubMed
- Cancer Res. 1980 Mar;40(3):717-21 - PubMed
- Br J Cancer. 1981 Jul;44(1):85-90 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials